&lt;Medizone International Inc> said it
acquired a patent that covers procedures for the use of the
Medizone Therapy in deactivating certain viruses commonly
associated with AIDS, hepatitis and herpes.
    The company said the patent covers procedures for the
deactivation of the viruses in human and animal blood, and the
treatment of stored blood prior to transfusion.
    Medizone said the acquisition is seen as a significant step
to enhance the company's proprietory position.
    The company said the patent was acquired from an unnamed
company involved in medical research and development for one
million shares of its common stock.

 Reuter
&#3;